Clinical Trial Detail

NCT ID NCT01989546
Title Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

pancreatic cancer

stomach cancer

prostate cancer

ovarian cancer

peritoneum cancer

breast cancer

Advanced Solid Tumor

Therapies

Talazoparib

Age Groups: senior adult

Additional content available in CKB BOOST